Introduction {#S1}
============

A key promise of human pluripotent stem cells (hPSCs), both human embryonic stem cells (hESCs) and induced pluripotent stem cells (hiPSCs), is their ability to access unlimited number of specialized cell types for application in cell-based therapies for neurodegenerative diseases such as Parkinson's disease (PD; [@B32]; [@B94]; [@B10]). The characteristic, patho-physiological feature of PD is the specific loss of midbrain dopamine (mDA) neurons in the substantia nigra (SN; [@B65]), leading to motor symptoms such as bradykinesia, tremor, and rigidity ([@B57]). Drug treatments, such as [L]{.smallcaps}-dopa, for restoring the dopamine deficiency is widely used to relieve disease symptoms, but long-term use shows decreased efficacy and can trigger debilitating side effects including motor complications as well as psychiatric problems ([@B78]).

Given the quite selective mDA neuron loss in PD, cell replacement may represent an attractive therapeutic strategy. There has been experience using various sources of cells for transplantation including adrenal medullary tissue and more importantly, human fetal midbrain tissue, starting with human clinical trials more than 30 years ago ([@B4]; [@B39]; [@B61]; [@B33]; [@B101]). More than 300 patients were transplanted using human fetal tissue world-wide, and despite variable results overall, some patients showed remarkable recovery obviating the need for any [L]{.smallcaps}-dopa treatment ([@B50]), and robust graft survival has been demonstrated histologically up to 24 years after transplantation ([@B60]). However, the use of human fetal tissue has several limitations such as transplantation of a heterogenous cell population, non-standardized tissue-processing, ethical issues associated with the routine use of fetal tissue, and importantly, the limited availability of suitable tissues. Therefore, alternative cell sources are urgently needed. The use of hPSCs is particularly attractive due to their ability to yield defined lineages such as mDA neurons at scale. Furthermore, hPSCs may provide a more practical and ethically acceptable cell source ([@B91]; [@B5]; [@B76]). The initial challenge in the use of hPSCs was the ability to direct their broad potential toward the restricted production of mDA neuronal lineages. Over the years, several groups have developed suitable protocols for mDA neuron production, and in ongoing or completed developments those protocols have been adapted to generate authentic and functional mDA neurons or precursors under clinical good manufacture practice (cGMP) grade conditions suitable for early stage human trials. Here, we discuss the tremendous progress made over the last decade, review the current bottlenecks, and provide a perspective for the future of developing cell replacement strategies in PD.

Brief History on mDA Neuron Protocol Development {#S2}
================================================

The initial approach to generate mDA neurons from hPSCs was based on adapting protocols from mouse ESC, which generate the neuronal-rosette like intermediates by co-culturing with feeder such as MS5 and PA6 and then further differentiate mDA neurons ([@B48]; [@B77]; [@B89]). While the rosette-based protocols could yield dopamine neurons that express TH, the rate-limiting enzyme for dopamine production, and showed dopamine release *in vitro*, those cells unlikely represented the correct cell type of origin as they barely expressed floorplate markers, such as FOXA2 and LMX1A. Importantly, rosette-derived dopamine (DA) neuron protocols displayed a considerable risk of neural overgrowth ([@B13]; [@B85]; [@B31]), and resulted in only limited *in vivo* DA neuron survival and function ([@B77]; [@B75]).

The realization that mDA neurons originate from the midbrain floor-plate ([@B73]; [@B11]) and the development of improved strategies to drive neural differentiation from hPSCs ignited the development of a new class of protocols. Those protocols used dual SMAD inhibition (inhibition of BMP and TGFβ signaling) for neural induction ([@B19]) together with patterning factors activating SHH (Sonic hedgehog), WNT, and FGF8b signaling ([@B55]; [Figure 1](#F1){ref-type="fig"}). The resulting floor-plate derived mDA cells showed the biochemical and electrophysiological properties of mDA neurons *in vitro* and resulted in more robust survival and function *in vivo* while reducing the risk of neural overgrowth or teratoma formation ([@B55]; [Table 1](#T1){ref-type="table"}). Since those initial studies, several groups have developed independent mDA neuron differentiation paradigms ([@B52], [@B53]; [@B92]; [@B29]; [@B44]; [@B90]; [@B21]; [@B67]; [@B37]; [@B88]) but all of those are based on the specification of mDA neurons via a floor-plate intermediate ([Figure 1](#F1){ref-type="fig"}).

![Comparison of published differentiation protocols for dopamine neuron derivation from human pluripotent stem cells. While all protocols use comparable strategies for neural induction (dual-SMAD inhibition) and for midbrain floor plate induction (activation of SHH pathway and WNT pathway), there are differences in the use of FGF8 (highlighted in pink) and the timing and concentration of the WNT activating compounds (typically CHIR99021; highlighted in yellow).](fcell-08-00729-g001){#F1}

###### 

Comparison of dopamine neuron transplantation paradigm in preclinical studies.

  Group       Cell Source              DIV at the time of injection   Cell Dosage for graft         Animal PD Model (Lesioning Method)     Trans-plant Location   Cell Quality Control                                                                                              Sorting Strategy (N/Y)          mDA Subtypes                                                                                                                         Other neuronal types/proliferating cells                                 References
  ----------- ------------------------ ------------------------------ ----------------------------- -------------------------------------- ---------------------- ----------------------------------------------------------------------------------------------------------------- ------------------------------- ------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------ -----------------
  Parmar      hESC (H9)                Day 16                         150,000--300,000 (Striatum)   Rat (6-OHDA MFB)                       Striatum               D14 mRNA expression                                                                                               N                               *Intrastriatal grafting* : 80% TH+GIRK2+; 10% TH+CALB+ among total TH+ ([@B41])                                                      PCNA+ (Quantification data N/A) ([@B53])                                 [@B41]; [@B53]
                                                                      50,000--75,000 (SNpc)         Rat (6-OHDA MFB)                       SN                                                                                                                                                                       *Intranigral grafting*: 60% TH+GIRK2+; 20% TH+CALB+ among total TH+ ([@B41])                                                                                                                                  
  Takahashi   hiPSC (healthy vs. PD)   Day 28                         400,000                       Rat (6-OHDA MFB)                       Striatum               80% FOXA2+LMX1A+ (D12); 80% FOXA2+ (D28); 40% TH+ (D42) ([@B29])                                                  Y (Corin @ D12)                 TH+GIRK2+ (Quantification data N/A) ([@B51])                                                                                         0.06 -- 0.07% Ki67+ GABA+, GFAP+ \<1% 1.2+/-0.8% 5-HT+ ([@B29])          [@B51]; [@B29]
                                                                      4.8M                          Monkey (MPTP IV injection)                                                                                                                                                                                                                                                                                                                                                                                                    
  Studer      hESC (H9)                Day 25                         150,000--200,000              Mouse (6-OHDA Striatum)                Striatum               FOXA2+LMX1A+\>60% (D11); 95% FOXA2+LMX1A+ (D25) 40% FOXA2+NURR1+ (D25); 80% TH+ (D50) 80% FOXA2+ (D50) ([@B55])   N                               TH+GIRK2+ and TH+CALB+ (Quantification data N/A) ([@B55])                                                                            5-HT (but hNCAM negative); GABA+ \<1% ([@B55])                           [@B55]; [@B90]
                                                                      250,000                       Rat (6-OHDA MFB)                                                                                                                                                                                                                                                                                                                                                                                                              
                                                                      7.5 M                         Monkey (MPTP Carotid followed by IV)                                                                                                                                                                                                                                                                                                                                                                                          
  Isacson     Autologous iPSC          Day 30 OR Day 49               10M--40M                      Monkey (MPTP IV administration)        Striatum               21-23% beta-tubulin+ (D28) 9% TH+ (D28) 1-2% TH+FOXA2+ (D28) ([@B45])                                             N                               FOXA2+TH+GIRK2+ (Quantification data N/A) ([@B92])                                                                                   No Ki67+ ([@B45])                                                        [@B45]; [@B92]
                                                                                                                                                                  51% beta-tubulin+ (D47) 7% TH+ (D47) 2% TH+FOXA2+ (D47) ([@B45])                                                                                                                                                                                                                                                                                                
  Kim         hiPSC                    Day 28                         100,000--300,000              Rat (6-OHDA MFB)                       Striatum               FOXA2 +LMX1A +\>80% (D28) 40% NURR1+ (D28) 20% TH+ (D28) ([@B88])                                                 N                               79.29+/− 4.88% TH+GIRK2+ among total TH+; TH+ALDH1A1+GIRK2+; TH+ALDH1A1+SOX6+; TH+ALDH1A1+CALB+ (Quantification data N/A) ([@B88])   5.9% Ki67+ 1.2% SOX1+Ki67+ 0.15% SOX6+PAX6+ No GABA+ or 5-HT+ ([@B88])   [@B88]
  Zhang       hESC (H9)                Day 32                         200,000                       Rat (6-OHDA SN)                        Striatum               EN1 +OTX2+ \>80% (D18) FOXA2 +LMX1A +\>80% (D18) TH+\>60% (D42) 90% FOXA2+EN1+ (D42) ([@B21])                     N                               TH+ALDH1A1+: 61.4+/− 4.8%; TH+GIRK2+: 56.3+/−6.7%; among total TH+ ([@B103])                                                         GABA \<1% 3.7+/−0.9% 5-HT+ 3.2+/− 0.1% GFAP+ ([@B21])                    [@B21]; [@B103]
  Parish      hESC (H9)                Day 20                         50,000                        Mouse (6-OHDA SN)                      Striatum               80% FOXA2 (D11) 90% FOXA2+ (D25) 30% TH+ (D25) ([@B37])                                                           Y (PITX3 ::GFP) (LMX1A ::GFP)   60% PITX3::GFP+GIRK2+; \<5% PITX3 ::GFP+CALB+; 20% PITX3::GFP +GIRK2+CALB+; ([@B37])                                                 502+/−11 5-HT+HNA+ cells ([@B37])                                        [@B37]

Representative studies are presented across different research groups that are working toward translating dopamine neuron cell therapy in PD. Comparison of key

in vitro

and

in vivo

parameters are presented based on the data taken from the published reports.

One interesting comparator to assess the potency of hPSC-derived mDA neurons was their preclinical assessment in direct comparison to the efficacy of human fetal tissue grafts showing comparable results in rescuing dopamine deficits in a PD rat model and in achieving proper target-specific neurite-outgrowth ([@B41]). In another set of studies, *in vivo* graft function of mDA cells was explored in preclinical PD animal models using more sophisticated technologies such as optogenetics ([@B90]) and chemogenetic manipulation ([@B21]). Those studies demonstrated conclusively that the recovery from PD behavior is dependent on neuronal activity and activity-dependent dopamine release from transplanted mDA cells. Finally, differentiation protocols to generate floor-plate-derived mDA neurons demonstrated their robustness and reproducibility by developing mDA cell products under conditions that should be suitable for cGMP manufacturing ([@B51]; [@B53]; [Figure 1](#F1){ref-type="fig"}). In an effort to promote the safe transition of hPSC-derived mDA neurons toward clinical testing in PD patients, a global effort, G-Force-PD was initiated in 2015 ([@B6]). G-Force-PD includes several groups from the United States, Europe, and Japan which all are leading independent efforts to bring hESC or hiPSC-derived mDA neurons to the clinic, but are committed to sharing their ongoing experience, discuss unexpected challenges and possible solutions, and propose guidelines ranging from cell manufacturing to clinical trials design ([@B5]). One of the groups within G-Force-PD has already started a first in human clinical cell transplantation trial in PD patients using iPSC-derived mDA neurons, with the first patient grafted in October 2018 ([@B69])^[1](#footnote1){ref-type="fn"}^. Another group has just recently published the feasibility of transplanting one single patient with its own iPSC-derived mDA neurons ([@B87]).

What Cell Type-Related Factors Are Critical for Clinical Translation? {#S3}
=====================================================================

Proper Patterning of mDA Precursors Beyond Establishing Floor-Plate Precursor Identity {#S3.SS1}
--------------------------------------------------------------------------------------

Although most protocols have been able to generate floor-plate precursors at high efficiency, various groups have used different timing, duration, and concentration of patterning factors, specially CHIR99021 (CHIR), the most widely used GSK3-inhibitor for triggering canonical WNT activation and recombinant factor FGF8 which is added in some but not other protocols for distinct time periods of differentiation ([Figure 1](#F1){ref-type="fig"}). The precise titration of CHIR is critical for proper rostro-caudal pattering during mDA neuron specification from hPSC. Work by the Parmar lab ([@B52]) demonstrated that different levels of WNT activation trigger dose-dependent changes in the regional identity of neuronal progenitor cells ranging from telencephalon (low WNT activation) to hindbrain (high WNT activation) fates, with the optimized CHIR concentration for mDA neuron induction defined as (0.7--0.8 μM). Furthermore, single cell RNA sequencing of Lmx1a+ precursors in the mouse suggests that the midbrain floor-plate markers FOXA2 and LMX1A are not specific to just mDA progenitors, but also mark the more anterior, subthalamic nucleus (STN) precursors which go on to give rise to glutamatergic neurons ([@B49]). Those results are in agreement with the idea that the midbrain-diencephalic floor-plate region is subdivided into two distinct domains by En1 for posterior, midbrain (mDA) identity, and Dbx1 for STN neuron population ([@B70]). Importantly, lowering CHIR exposure (0.4--0.6 μM) resulted in a bias toward Lmx1a+/Pitx2+ positive cells (STN neuron) while the percentage of STN neurons was greatly decreased at higher concentrations of CHIR (0.8--1 μM) with increased efficiencies of mDA neuron differentiation ([@B49]). Nevertheless, a broad range of concentrations and durations of CHIR treatment have been proposed across for mDA neuron derivation from hPSCs as detailed in [Figure 1](#F1){ref-type="fig"}. There are several possibilities for those discrepancies across protocols. In particular, the basal media composition (KSR versus N2 versus E6 media), coating substrates (Matrigel versus LAM511) and the total lengths of CHIR treatment likely contribute to those differences.

Studies, using bulk-RNA sequencing of mDA neurons at the time of grafting demonstrated a correlation of improved *in vivo* graft outcome, across \>30 batches, for mDA neuron populations expressing more caudal floor-plate markers including expression of EN1 ([@B53]). Furthermore, the same study showed that FGF8b treatment after floor-plate induction could more reliably induce caudal marker expression. These results were consistent with previous work suggesting the need for FGF8 treatment at later time points of differentiation during non-human primate mDA neuron induction ([@B103]; [Figure 1](#F1){ref-type="fig"}). In contrast, earlier exposure of FGF8b during mDA patterning may not impact the robustness of midbrain marker expression ([@B55]). One challenge of protracted FGF8b treatment is the fact that FGF8b is highly expressed in the hindbrain during early development ([@B62]). Therefore, induction of hindbrain markers, such as HOXA2 and GBX2, can occur following high dose FGF8b treatment ([@B53]). Thus, the use of FGF8 needs to be very carefully timed and titrated to avoid hindbrain and potentially other FGF8-driven proliferative contaminants. Alternatively, it may be possible to find alternative strategies such as the use of midbrain-specific FGFs ([@B62]) to substitute for late FGF8b treatment or to develop strategies to selectively enrich for the desired phenotype for translational applications.

Another remaining challenge is to selectively generate populations of specific mDA neuron subtypes including A9 (SN) or A10 (Ventral tegmental area; VTA) mDA neurons. A9 mDA neurons are particularly vulnerable in PD ([@B26]; [@B93]) and are the main cell type of interest for cell therapy. Thus far, most studies used immunolabeling for two widely used markers, GIRK2 for A9 and CALBINDIN for A10 ([@B24]) to characterize mDA neurons subtypes *in vitro* or upon transplantation. Several studies reported the presence of ∼60--80% of GIRK2 + TH + neurons and ∼10--20% of CALB1 + TH+ in dorso-striatal grafts after 4.5--6 months post hPSC-mDA neuron transplantation ([Table 1](#T1){ref-type="table"}). However, those two markers are likely insufficient to segregate A9 versus A10 identity, and they may be particularly less reliable at early, prenatal stages of development. Importantly, neither marker is suitable to prospectively distinguish mDA neuron subtypes at the time of transplantation.

Other subtype selective markers of interest include ALDH1A1, which has been defined as an A9 type marker ([@B25]; [@B103]; [@B88]). Both ALDH1A1 and the transcription factor SOX6 have been reported as specific molecular determinants expressed at the mDA neuron progenitor stage, marking precursors that later develop into ventro-lateral A9-type SN neurons ([@B74]; [@B9]). Accordingly, several studies strived to induce the expression of ALDH1A1 and SOX6 during hPSC-differentiation. R-Spondin 2 ([@B43]) and BMP5/7 ([@B47]) were reported as candidate inducers of ALDH1A1 and SOX6 respectively *in vitro*. R-Spondin 2 treatment during floor-plate patterning increased ALDH1A1 expression by 5-fold compared to control by gene expression, but it remained unclear how those gene expression changes correspond to protein expression. Therefore, it will be important to determine the total numbers of ALDH1A1+/TH+ neurons that can be achieved under those conditions and the level of their functionality *in vivo* ([@B43]). Similarly, despite promising data in the mouse, where BMP signaling mutants showed reduced numbers of A9 neurons postnatally, BMP5/7 exposure appeared to have minimal effects on enriching A9 mDA neurons *in vitro* and without clear information on the percentages of SOX6 + TH + neurons that can be obtained under those conditions ([@B47]).

Despite many years of work using GIRK2, SOX6, and ALDH1A1 as individual A9 markers to characterize mDA neurons, the growing number of scRNAseq studies on mDA neuron subtypes ([@B81]; [@B56]; [@B98]) indicate that it is essential to multiplex markers for reliable subtype identification. For example, ALDH1A1 and SOX6 single positive cells can be found both in VTA and SN domains, whereas co-expression should identify SN neurons at the ventro-lateral location within the midbrain ([@B80]). Given the availability of multiple protocols to efficiently derive floor-plate-derived mDA precursors, a key next step is to define the signaling cascades that restrict those precursors into pure mDA neurons (versus other floor-plate-derived neuronal lineages) and further into selective mDA neuron subtypes. Those efforts should go hand in hand with improved strategies to identify markers that capture stage and subtype identity during early developmental stages, stages relevant for cell transplantation.

Homogenous mDA Cell Population {#S3.SS2}
------------------------------

The application of hPSC derivatives in human patients has progressed slowly due to potential risks associated with the use of pluripotent stem cells, where a few contaminating hPSCs could proliferate and develop into a teratoma or into early stage neuroepithelial tumors ([@B13]; [@B89]; [@B31]). Furthermore, the transplantation of heterogenous neuronal population may entail the risk of side effects such as graft-induced dyskinesia ([@B30]) which have been attributed to the presence of serotonergic neurons in fetal grafts, as documented in grafted human PD patients by histological analysis and by functional studies using pharmacological and PET based assays ([@B79]). Without understanding the potential risks and side-effects that could come from "off-target" neuronal or non-neuronal populations, most groups strive to produce highly enriched and defined mDA neuron populations and to eliminate any contaminating cells to assure safety for clinical translation. Several strategies have been proposed to avoid unwanted cells either via enriching floor-plate or later stage mDA precursors using a surface marker ([@B29]; [@B86]; [@B58]) or via eliminating remaining undifferentiated hPSCs by exposing cultures during mDA neuron differentiation with natural compound, quercetin ([@B88]). Those studies reported that purified mDA progenitors resulted in more homogenous graft size and mDA neuron density as well as in improved recovering motor dysfunctions in PD animal models than non-sorted cells without evidence of any tumor formation ([@B29]; [@B86]; [@B58]). However, while some markers such as Corin can enrich for floor-plate precursors, and NCAM or ALCAM ([@B16]) can enrich for certain neural cells, none of the currently available markers seems to be truly specific for mDA neuron lineage. Accordingly, there is currently no consensus on any strategy to enrich for mDA neurons reliably and new technologies will be needed for successful clinical translation. One strategy that appears capable of generating near homogenous populations of mDA neurons is to use genetic reporter PSC lines that mark either mDA progenitors or their post-mitotic progeny. We have recently reported that NURR1 (NR4A2) can serve as a reliable marker of early post-mitotic mDA neurons under floor-plate differentiation conditions. An NURR1:H2B-GFP reporter line allowed enrichment of mDA neurons *in vitro* that yielded nearly pure populations based on mDA markers such as FOXA2, LMX1A, NURR1 and TH including by using flow based and sc-RT-qPCR analyses ([@B83]). While genetic engineering and FACS-based purification of neurons presents major challenges of human translation, it may be possible to adapt this approach for MACS-based or genetic selection strategies more suitable or translation. In either case, the use of genetic reporters is a powerful tool to define the appropriate stage of mDA neuron development for transplantation (see below). Similarly, once we better define early markers that can segregate mDA neurons, we can also apply those and other novel markers to selectively isolate A9-versus A10 type mDA neurons *in vitro*.

Stage of mDA Cell for Grafting {#S3.SS3}
------------------------------

Over the last decades, fetal tissue transplantation studies have provided tremendous insights how to reconstruct the damaged brain of a PD patient. One such aspect was the discovery of the optimal window for isolating mesencephalic cells from fetal tissue. Human mDA neurogenesis occurs during a narrow window of early CNS development at week 6--8.5 p.c. ([@B72]; [@B35]). Interestingly, human fetal grafts derived from tissue later than 9 weeks showed reduced survival, particularly when injected as cell suspension, and did not reliably yield functional mDA neurons *in vivo* ([@B34]; [@B3]; [@B71]). In contrast, tissue derived from fetuses at 5.5--8 weeks p.c. has yielded the best results in pre-clinical and clinical results with robust survival of mDA neuron rich grafts. One additional important point regarding the age of the donor may be the differential yield in production of mDA neuronal subtypes. Rodent studies have implicated that the younger E10 tissue gave rise to ∼75% GIRK2 + mDA neurons in intrastriatal grafts whereas older E12 tissue contributed 60% of GIRK2 + mDA neurons possibly due to staggered birth timing of A9 versus A10 mDA neurons ([@B38]; [@B17]).

Given the extensive push to develop floor-plate derived mDA neurons from hPSCs, it is essential to address questions about optimal stage of *in vitro*-derived cells for transplantation. From a simple, regenerative medicine perspective, one could argue that it makes the most sense to replace what is lost in PD, which are mature mDA neurons. However, as learned from the fetal tissue experience, mature mDA neurons may not survive upon transplantation into the adult brain, and thereby do not represent a viable option.

To systematically determine the optimal stage for transplantation, we previously reported in mouse ESCs on a side-by-side comparison of the engraftment potential of Hes5:GFP + progenitors, vs Nurr1 + neuroblasts vs Pitx3 + mDA neurons *in vivo* ([@B36]). Pitx3 + mDA neurons survived only poorly resulting in smaller grafts with lower numbers of total mDA neurons and with worse behavioral data in drug-induced rotation tests as compared to both Hes5 + or Nurr1 + grafts. Our results indicated that Nurr1 may capture a suitable stage for transplantation while Pitx3 marks mDA neurons that are too mature for efficient *in vivo* engraftment. Interestingly, the Pitx3 finding was recently confirmed in an independent study using human ESC genetic reporter lines for PITX3 and for LMX1A ([@B27]). While PITX3 + mDA neuron showed very poor survival, LMX1A + cells at the floor-plate precursor stage showed efficient engraftment, albeit the resulting grafts (similar to Corin + grafts) were far from representing pure mDA neuron grafts ([@B37]).

The identification of Nurr1 + stage a suitable for grafting has been translated into human PSC-based differentiation studies where mDA neurons were isolated at day 25 of differentiation, the stage of high NURR1 expression when most cells have started to exit cell cycle. Such early post-mitotic neurons appear to produce rich mDA neuron grafts and have resulted in successful rescue of complex motor abnormalities in animal PD models including mice, rat, and monkey ([@B55]; [@B36]; [@B90]). Other teams such as the group by Isacson and Kim used similar strategy to transplant their cells after expanding mDA progenitors for a certain period ([@B88]). Jun Takahashi's group transplanted later, day 28 mDA "progenitors," which are differentiated further starting from floor-plate progenitor stage sorted by CORIN at day 12 ([@B29]; [@B51]). In contrast, the Parmar team demonstrated that relatively early stage, day 16 mDA progenitors, just beyond floor-plate precursor stage are also suitable for intracerebral transplantations ([@B52], [@B53]; [@B41], [@B42]; [@B18]; [@B2]). Despite the relatively earlier time point for transplantation, the protocol strives to transition the progenitors toward a "neural" fate via concurrent treatment of FGF8b ([@B53]; [@B68]), BDNF, and ascorbic acid (AA) ([@B104]) for about a week to achieve progenitor cell expansion and *in vitro* differentiation toward mDA neuron stage. In conclusion, the transplantation of the cells starting from late midbrain floor-plate to an mDA neuroblast stage or early mDA neuron may be all suitable for robust survival and function, but additional side-by-side transplantation studies using human PSCs will be required to fully explore this point, particularly for the mDA stage-dependent extent of DA fiber outgrowth and synaptic integration.

A parallel strategy to further improve graft composition is the generation of extensive molecular data on hPSC-derived mDA cells prior to transplantation and correlating those data with the subsequent performance of grafted cells ([@B53]; [@B99]). This strategy should allow the iterative optimization of graft composition to fine-tune both subtype identity and stage of the grafted cells for optimal functional results. Such technology can also be further combined with the use of prospective lineage tracking and barcoding methods to link cell identity to graft outcome.

Location of the Cell Injected {#S3.SS4}
-----------------------------

Cell transplantation in PD has mainly focused on ectopic placement of cells within the striatal target region, far away from the site of degeneration in the SN. The rationale for this approach arose from the concern that the extent of the mDA axonal outgrowth from the graft may not suffice to efficiently innervate the human caudate or putamen. Additionally, in some of the studies, DA neurons did not survive as well when grafted in the midbrain compared to striatum ([@B97]). Furthermore, grafting studies over the last decade have demonstrated that intra-striatal grafting of fetal tissue is sufficient for restoring striatal dopamine release and inducing recovery from PD-relevant symptoms at least a subset of patients ([@B50]). Ectopic transplantation, however, raises the concern that grafted cells may lack major afferent inputs of endogenous mDA neurons in SN, inputs known to play important roles in phasic regulation of nigrostriatal neuron activity. This lack of afferent control may restrict the ability of the cells to improve more complex motor behaviors ([@B102]; [@B8]). Furthermore, there is increasing evidence that DA released from dendrites locally in the SN may have important physiological functions distinct from striatal DA release ([@B22]). Therefore, several groups have pursued a long-term goal of orthotopic transplantation using hPSCs-derived mDA cells into the SN.

The Parmar group demonstrated that mDA progenitors grafted into the murine SN can extend long axons over 10 mm from the graft core innervating various rat brain structures including caudate-putamen, nucleus accumbens, and amygdala ([@B42]). Using pseudo rabies-virus-based retrograde, monosynaptic tracing technology ([@B42]; [@B18]), they demonstrated the establishment of afferent inputs on the grafted cells from the host starting by 6 weeks post transplantation ([@B42]). Those inputs appear largely dependent on graft placement ([@B42]; [@B18]). However, it remains unclear to what extent differences in afferent synaptic inputs, such as exaggerated thalamic but reduced hypothalamic and raphe inputs, affect the functional behavior of striatal versus nigral placed mDA cell grafts ([@B2]).

Furthermore, the behavioral readouts in intranigral grafting studies were typically limited to drug-induced rotation tests, which are not dependent on afferent input of the transplant ([@B102]). Therefore, it would be interesting to test whether intranigral grafting can trigger rescue of more complex motor behaviors and whether those are dependent on afferent input or possibly on nigral DA release. Additionally, the human brain is much larger than rodent or primate brains, and thus homotopic grafting may be more challenging to achieve meaningful projections from the SN to appropriate regions within the striatum such as the post-commissural putamen. In human fetal tissue grafting studies, SN injections have been attempted but only in combination with striatal injections ([@B64]), which makes it difficult to assess the relative contribution of each site to any clinical parameters. However, the technology to deliver hPSC-derived mDA progenitors in the SN will likely improve, and optimization of graft composition, the addition of growth promoting factors or even exercise of the host brain may contribute to achieve reliable restoration of the nigro-striatal circuit ([@B100]).

mDA Cell Dosage for Transplantation {#S3.SS5}
-----------------------------------

Typically, 200,000--420,000 dopamine neurons reside in human midbrain, and it is estimated that 50% loss of those DA neurons leads to the PD symptom ([@B14]). According to preclinical studies using fetal tissue or hPSC-derived mDA cell, 1200--2400 surviving TH + neurons in rat, 13,000 in primate, 40,000--80,000 in the human brain may be required to achieve a meaningful therapeutic effect ([@B45]; [@B46]). The current bottleneck in delivering cells to the brain is that typically less than 10% of grafted mDA neurons survive following transplantation ([@B15]; [@B97]; [@B44]). Multiple factor may contribute to poor mDA neuron survival including mechanical trauma, growth factor deprivation, initial lack of vascularization, hypoxia and free radical production, or excessive extracellular concentrations of excitatory amino acids in the host brain ([@B15]).

The Takahashi group embarked on the first human clinical trial by injecting 2.4 million iPSC-derived mDA cells in 2018. The Kim group injected 4 million iPSC-derived mDA precursors in one patient ([@B87]). Upcoming human clinical trials in New York and Europe propose two different starting doses -- high and low -- for their proposed early stage (Phase I/IIa) clinical trials to assess the feasibility and safety of various dosages ([@B5]). Several studies have been proposed to enhance fetal or PSC-derived mDA neuron grafts such as by promoting their survival or function. Examples include treatment with pifithrin-alpha, increase of polysialic acid levels ([@B23]; [@B7]), or delivery of neurotrophic factors such as glial cell line-derived neurotrophic factor (GDNF) which may provide benefits to facilitate graft integration and functional recovery ([@B84]; [@B82]; [@B37]).

Next Generation of mDA Cell Products {#S4}
====================================

Immuno-Compatible mDA Neuron {#S4.SS1}
----------------------------

Past clinical fetal and hPSC-based studies have mostly focused on the use of allogenic cell sources for transplantation. Given the relatively mild reaction to allogenic grafts in the CNS, the use of only transient immunosuppression offers long-term graft survival for \>20 years ([@B60]). In fact, some groups have performed fetal transplantation without any immunosuppression and showed long-term graft survival, albeit possibly with reduced mDA neuron numbers. Studies in the mouse ([@B95]) and in primates ([@B66]) showed concordant results suggesting that allografting results in mDA neuron survival but at lower rates, particularly if there is a considerable mismatch between host and graft. While those differences seem to disappear in the presence of transient immunosuppression ([@B66]) grafting matched cells back into non-human primate hosts has been demonstrated by several groups ([@B45]; [@B51]) and most recently in one human individual ([@B87]).

However, an isogenic mDA neuron approach raises the issue whether those patient-specific neurons may have a genetic predisposition that will make them more prone to succumb to disease after transplantation. In addition, such an approach is labor intensive and costly which will complicate future clinical implementation. In particular, it will be more difficult to establish extensive safety data for the cells in each individual patient and thereby increase clinical risk. Instead, transplantation of human leucocyte antigen (HLA)-matched iPSC-derived mDA cells has been proposed to minimize the risk of allograft rejection ([@B96]). There are several ongoing efforts world-wide to establish HLA-homozygous iPSC lines that can match large proportions of the overall population. In fact, the first human clinical trial in Japan made use of one such HLA-homozygous lines for transplantation in PD ([@B69]), albeit still using transient immunosuppression.

Alternatively, there is considerable excitement in generating universal hPSC lines, which may provide immune tolerance without any immunosuppression. Using such an approach, theoretically, mDA neurons from a single universal hPSC line could be administrated to any PD patient worldwide. Proof-of-concept in establishing universal hPSC has achieved either by the combination of B2M gene knock-out with HLA-E overexpression ([@B40]) or by knock-out of major histocompatibility complex (MHC) class I/II with CD47 (do not eat me signal) overexpression ([@B28]). Given the potential of such engineered, universal cells to escape immune surveillance, implanting these cells should be pursued very carefully to avoid concerns regarding safety. In fact, those strategies are typically combined with integrating a drug-induced suicide switch in the cells as a failsafe ([@B40]; [@B28]).

Pathology-Resistant mDA Neuron {#S4.SS2}
------------------------------

Lewy body formation is well known as one of the neuro-pathological hallmarks in PD ([@B12]), Interestingly, while no disease pathology was observed in PD patients over the first 10 years after transplantation, Lewy bodies have been identified in human fetal tissue grafts starting 11--16 years after the cell therapy with increasing percentages of affected cells by \>20 years post grafting. As grafted cells were fetal tissue-derived and unlikely to have a PD predisposition, such Lewy body pathology suggests host-to-graft disease propagation ([@B54]; [@B59]). While progressing very slowly, such transmission could ultimately be toxic to transplanted mDA cells and limit the long-term efficacy of the cell therapy. Previous work suggests that both cytoplasmic insoluble and endogenous soluble alpha-synuclein protein is necessary to form the Lewy body and exert toxic effects on mDA neurons ([@B63]). Therefore, SNCA (alpha-synuclein) knockout (KO) or knock-down hPSC lines ([@B20]) may be an attractive strategy to yield pathology-resistant mDA neurons. The feasibility of this approach is further supported by the lack of major functional deficits in SNCA KO mice ([@B1]).

Pure Substantia Nigra (A9-type) mDA Neuron {#S4.SS3}
------------------------------------------

Recently, single cell gene profiling has been used to define subtype compositions during mouse and human midbrain development ([@B81]; [@B56]; [@B49]; [@B98]). Such technology extended the previous molecular definition of mDA neurons and enabled to further divide SN and VTA region into seven distinct molecular clusters ([@B80]). However, to what extent these molecular findings can be translated into hPSC-derived mDA neuron development remains unexplored. This is illustrated when profiling of hPSC-derived mDA neurons in La Manno et al., which seem to recapitulate key stages of *in vivo* ventral midbrain development. However, those cell preparations expressed many poorly defined radial glial and neuroblast markers and differed from the *in vivo* phenotypes in gene expression ([@B56]). Additionally, ALDH1A1 was not expressed in any of those PSC-derived mDA cells. This result may be due to the *in vitro* culture environment that does not fully support mDA neuron development or lack of proper induction of certain subtype-specific genes. In either case, those results indicate that there is considerable room for further improvements in mDA neuron derivation and maturation strategies.

The developmental ontogeny of distinct mDA neuron subtypes remains a long-standing question in the field. Now with rapidly evolving high throughput sequencing technology and lineage tracking tools, it becomes possible to revisit questions about ontogeny and to monitor the developmental trajectory at a single cell resolution from the acquisition of mDA precursor stage both *in vitro* to a fully functional mDA neurons many months after transplantation *in vivo*. Such data should enable a next generation of mDA neuron protocols to reap the full benefit of this approach for human clinical transplantation studies of the future.

Conclusion {#S5}
==========

Given the extensive history of cell replacement therapy using human fetal tissue and the rapid recent advances in human stem cell technology, there is considerable current activity around establishing and translating clinical-grade protocols into early stage trials in PD patients. However, despite the progress made thus far and results from the first clinical studies emerging soon, the scientific effort to develop improved grafting strategies should not stop here. It remains essential to carefully consider and address remaining bottlenecks in the field as reviewed in this article. Next generation of mDA cell products should address those remaining barriers on the road to making cell replacement possibly a routine therapeutic strategy that could become available to PD patients world-wide. Only if basic and translational efforts continue hand in hand, we will be able to capture the full potential of this approach in PD and pave the way for other regenerative approaches in brain repair.
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